Disease Domain | Count |
---|---|
Neoplasms | 5 |
Nervous System Diseases | 4 |
Endocrinology and Metabolic Disease | 2 |
Infectious Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 3 |
Chemical drugs | 1 |
Synthetic peptide | 1 |
Recombinant polypeptide | 1 |
Synthetic peptide vaccine | 1 |
Target |
Mechanism CCK antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org.- |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Sep 2025 |
Sponsor / Collaborator |
Start Date01 May 2025 |
Sponsor / Collaborator |
Start Date01 Jul 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
GPR173 ( CCK ) | Brain Diseases More | Preclinical |
Covid-19 polytope vaccine(Fuyang Normal University/City University of Hong Kong) | COVID-19 More | Preclinical |
POZ-NO | Neoplasms More | Preclinical |
US20240110200 ( GPR173 )Patent Mining | Nervous System Diseases More | Discovery |
US20240415918 ( CCK receptor )Patent Mining | Nervous System Diseases More | Discovery |